Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Show more
Location: Kungsbron 1, Stockholm, 111 22, Sweden | Website: https://www.calliditas.se/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$40.00
Open
$40.00
Volume
N/A
Day Range
$40.00 - $40.00
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
3.81%
Institutional Own.
0.32%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | Approved Quarterly sales | |
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | Approved Quarterly sales | |
Setanaxib Details Primary biliary cholangitis, Liver disease | Phase 2b Update | |
Setanaxib Details Alport Syndrome | Phase 2 Data readout | |
Setanaxib Details Idiopathic pulmonary fibrosis | Phase 2 Update | |
Setanaxib Details Cancer, Solid tumor/s, Head and neck squamous cell carcinoma | Phase 2 Update |